FMIBlog5d
Global Electrophoresis Market Poised for Strong Growth, Expected to Reach USD 3,523.50 Million by 2033 at a CAGR of 4.5% | FMI
The global electrophoresis market is set to witness substantial growth, with its valuation projected to rise from USD 2,268.8 million in 2023 to USD 3,523.50 million by 2033. This expansion reflects a ...
eLife6d
Genome organization by SATB1 binding to base-unpairing regions (BURs) provides a scaffold for SATB1-regulated gene expression
Mammalian genomes are organized by multi-level folding, yet how this organization contributes to cell type-specific transcription remain unclear. We uncovered that the nuclear protein SATB1 ...
Manchester looks to build on life sciences cluster effect
Nevertheless, Manchester’s life sciences cluster has bounced back and evolved following AstraZeneca’s departure, Sheppard ...
Arabian Post8d
Catalonia’s Biotech Sector Flourishes as Barcelona Emerges as a Leading Life Sciences Hub
Dubai Catalonia has solidified its position as a prominent biotechnology hub, with Barcelona at its epicenter, fostering ...
EuropaWire11d
QIAGEN Gains FDA Approval for New QIAstat-Dx Gastrointestinal Panel 2 Mini B, Expanding Syndromic Testing Options
QIAGEN has received FDA approval for its QIAstat-Dx Gastrointestinal Panel 2 Mini B, expanding its syndromic testing offerings for gastrointestin ...
Credence Research Inc.: Microplates Market to Reach USD 1,301.08 million by 2032, Growing at an 4.50% CAGR - Credence Research
The Global Microplates Market is experiencing steady growth, driven by the increasing adoption of high-throughput screening (HTS) in drug discovery ...
DutchNews.NL13d
QIAGEN receives U.S. clearance for second QIAstat-Dx mini gastrointestinal panel, expanding U.S. syndromic testing portfolio
Automation solutions bring these processes together into seamless and cost-effective workflows. QIAGEN serves over 500,000 ...
EuropaWire15d
QIAGEN Files Lawsuit Against bioMérieux to Protect Key Innovations in TB Detection Technology
QIAGEN has filed a lawsuit against bioMérieux in the German Unified Patent Court to protect its QuantiFERON technology, specifically its Europea ...
Business Wire15d
QIAGEN takes legal action to defend QuantiFERON intellectual property and protect innovations in latent tuberculosis testing
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has filed a complaint against bioMérieux S.A. (EPA: BIM) for patent in ...
Nasdaq15d
QIAGEN Files Patent Complaint Against BioMérieux To Protect QuantiFERON Technology
(RTTNews) - QIAGEN N.V. (QGEN) announced that it has filed a complaint against bioMrieux S.A. for patent infringement, reinforcing its commitment to protecting the scientific advancements behind ...